[12] [13] The Medicines and Healthcare products Regulatory Agency (MHRA) and the European Medicines Agency (EMA) continue to monitor the safety profile of GLP-1 agonists through routine pharmacovigilance
Here you can find answers on frequently asked questions
Poor sleep increases hunger (via higher ghrelin and lower leptin), raises cortisol levels that promote fat storage, and reduces willpower and recovery, making it harder to stick to healthy habits
International Expansion The company is expanding internationally aggressively as well
Several studies have shown that complete withdrawal of an obesity treatment dose of a GLP-1RA without other structured care leads to weight regain in most people.2 However, it remains unclear whether lifelong treatment of obesity should always consist of GLP-1RAs at full obesity dosing or whether a range of alternative strategies can enable some subset of people with obesity to maintain their weight loss after a limited duration of initial treatment, followed by tapering, discontinuing, or off-ramping these agents." This paragraph from the article, I believe, sums up nicely what this means
As a transcription factor, MAT1 negatively regulates cytochrome P450 2E1 (CYP2E1) at the mRNA level
